An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa

• Published in: Journal of lower genital tract disease Vol. 20; no. 1; p. 31
• Main Authors: Coleman, Jenell S, Cespedes, Michelle S, Cu-Uvin, Susan, Kosgei, Rose J, Maloba, May, Anderson, Jean, Wilkin, Timothy, Jaquet, Antoine, Bohlius, Julia, Anastos, Kathryn, Wools-Kaloustian, Kara
• Format: Journal Article
• Language: English
• Published: United States 01.01.2016
• Subjects: Africa South of the Sahara; Cross-Sectional Studies; Early Detection of Cancer; Female; Health Facilities; Health Services Research; Humans; Surgical Procedures, Operative; Uterine Cervical Neoplasms - diagnosis; Uterine Cervical Neoplasms - therapy
• ISSN: 1526-0976
• DOI: 10.1097/LGT.0000000000000165

Approximately 85% of cervical cancer cases and deaths occur in resource-constrained countries where best practices for prevention, particularly for women with HIV infection, still need to be developed. The aim of this study was to assess cervical cancer prevention capacity in select HIV clinics located in resource-constrained countries. A cross-sectional survey of sub-Saharan African sites of 4 National Institutes of Health-funded HIV/AIDS networks was conducted. Sites were surveyed on the availability of cervical cancer screening and treatment among women with HIV infection and without HIV infection. Descriptive statistics and χ or Fisher exact test were used as appropriate. Fifty-one (65%) of 78 sites responded. Access to cervical cancer screening was reported by 49 sites (96%). Of these sites, 39 (80%) performed screening on-site. Central African sites were less likely to have screening on-site (p = .02) versus other areas. Visual inspection with acetic acid and Pap testing were the most commonly available on-site screening methods at 31 (79%) and 26 (67%) sites, respectively. High-risk HPV testing was available at 29% of sites with visual inspection with acetic acid and 50% of sites with Pap testing. Cryotherapy and radical hysterectomy were the most commonly available on-site treatment methods for premalignant and malignant lesions at 29 (74%) and 18 (46%) sites, respectively. Despite limited resources, most sites surveyed had the capacity to perform cervical cancer screening and treatment. The existing infrastructure of HIV clinical and research sites may provide the ideal framework for scale-up of cervical cancer prevention in resource-constrained countries with a high burden of cervical dysplasia.